Japan’s Hisamitsu a pharmaceuticals and health goods manufacturer, has announced the purchase of US Miami-based Noven Pharmaceuticals for $430m.
The venture to make Noven a wholly owned subsidiary is part of Hisamitsu’s goal of growing its presence in the US.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Hisamitsu will pay $16.50 for each Noven share, representing a 38% premium on Noven’s 50-day moving average share price of $11.95.
The deal would make Noven a wholly owned subsidiary when completed in August, raising Hisamitsu’s stake in the firm up from its current 4.98% stake.
Noven, which specialises in hormone therapies for women as well as drug delivery patches, will name Jeffrey Eisenberg as president and chief executive and will remain a standalone business.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
